Aktion

Recombinant Human DLL4 Protein(Fc Tag)

Recombinant Human DLL4 Protein(Fc Tag)
Artikelnummer
ELSPDMH100304-500
Verpackungseinheit
500μg
Hersteller
Elabscience Biotechnology

Verfügbarkeit: wird geladen...
Preis wird geladen...

Special promotion: Enjoy a 10% discount on Elabscience recombinant proteins through September 30, 2025.
Promo code: ELABPQ3
No additional discounts available during this period.

Protein Tag: C-Fc

Uniprot: Q9NR61

Accession: Q9NR61

Background: Delta-like protein 4 (DLL4 , Delta4) , a type I membrane-bound Notch ligand , is one of five known Notch ligands in mammals and interacts predominantly with Notch 1 , which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a "brake" on VEGF-induced vessel growth , forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore , the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions , such as cancer , DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis , but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies , blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density , yet causes marked growth inhibition due to functionally defective vasculature. Thus , DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.

Bio Acitivity: Not validated for activity

Sequence: Ser27-Pro524

Purity: > 90% as determined by reducing SDS-PAGE.

Formulation: Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.

Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Endotoxin: < 1.0 EU/mg of the protein as determined by the LAL method.

Calculated MW: 79.7 kDa

Observed MW: 90 kDa
Mehr Informationen
Artikelnummer ELSPDMH100304-500
Hersteller Elabscience Biotechnology
Hersteller Artikelnummer PDMH100304-500
Verpackungseinheit 500μg
Mengeneinheit STK
Produktinformation (PDF)
×
MSDS (PDF)
×